Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

ZILBRYSQ

ZILUCOPLAN SODIUM

Standard Dose
EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZILBRYSQ is listed in Drugs@FDA under application 216834 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ZILUCOPLAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) Sponsor UCB INC Submission history Latest submission status date: 2026-01-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZILBRYSQ is listed in Drugs@FDA under application 216834 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ZILUCOPLAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) Sponsor UCB INC Submission history Latest submission status date: 2026-01-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ZILBRYSQ (ZILUCOPLAN SODIUM) | Drug Monograph | MedicHelpline